DES Utilization Guidelines Give Guidant Comfort; J&J Revisits Cypher Pricing
This article was originally published in The Gray Sheet
Executive Summary
Guidant is positioning its Multi-Link bare-metal stent platform to benefit from hospital guidelines limiting drug-eluting stent use to FDA-approved indications
You may also be interested in...
J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus
J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus
Future DES Purchasing Strategy: A “Price Is Right” Approach?
Pricing strategies and ease of use factors likely will overshadow clinical efficacy as Boston Scientific and Johnson & Johnson joust for dominance in the U.S. drug-eluting stent market